Results 241 to 250 of about 217,185 (304)

Discontinuing Long‐Term Denosumab in Treating Fragile Bone: Why, for Whom, and How?

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Discontinuation of denosumab (Dmab) may be necessary due to adverse events or an unfavorable long‐term risk–benefit profile. However, accumulating evidence demonstrates pronounced rebound phenomena after withdrawal, most notably a marked increase in multiple vertebral fractures, and, in some reports, elevated mortality.
Ko‐Hsiu Lu   +5 more
wiley   +1 more source

Opioid dose, duration, and risk of use disorder in Medicaid patients with musculoskeletal pain. [PDF]

open access: yesPain Med
Perry A   +10 more
europepmc   +1 more source

Randomized feasibility trial of tele-yoga versus in-person yoga for treating chronic musculoskeletal pain in veterans. [PDF]

open access: yesBMC Complement Med Ther
Mahoney L   +14 more
europepmc   +1 more source

Whole-body biomechanical and lifestyle predictors of pediatric musculoskeletal pain: a multi-center cross-sectional study. [PDF]

open access: yesFront Public Health
Kardm SM   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy